Table 3 Duration of response in patients with laBCC receiving sonidegib 200 mg daily by central review
mRECIST criteria | ERIVANCE-like criteria | |
|---|---|---|
DOR, median, months, (95% CI) | 26.1 (NE) | 26.1 (NE) |
Event-free probability estimate, %, (95% CI) | ||
6 months | 86.4 (67.7–94.7) | 90.8 (74.1–96.9) |
9 months | 74.9 (54.4–87.2) | 83.8 (65.3–93.0) |
12 months | 64.9 (42.3–80.4) | 69.2 (46.5–83.8) |